271 related articles for article (PubMed ID: 29666172)
1. Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis.
Lannagan TRM; Lee YK; Wang T; Roper J; Bettington ML; Fennell L; Vrbanac L; Jonavicius L; Somashekar R; Gieniec K; Yang M; Ng JQ; Suzuki N; Ichinose M; Wright JA; Kobayashi H; Putoczki TL; Hayakawa Y; Leedham SJ; Abud HE; Yilmaz ÖH; Marker J; Klebe S; Wirapati P; Mukherjee S; Tejpar S; Leggett BA; Whitehall VLJ; Worthley DL; Woods SL
Gut; 2019 Apr; 68(4):684-692. PubMed ID: 29666172
[TBL] [Abstract][Full Text] [Related]
2. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
3. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
[TBL] [Abstract][Full Text] [Related]
4. Serrated pathway in colorectal carcinogenesis.
Yamane L; Scapulatempo-Neto C; Reis RM; Guimarães DP
World J Gastroenterol; 2014 Mar; 20(10):2634-40. PubMed ID: 24627599
[TBL] [Abstract][Full Text] [Related]
5. Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer.
Wong JJ; Hawkins NJ; Ward RL; Hitchins MP
Mod Pathol; 2011 Mar; 24(3):396-411. PubMed ID: 21102416
[TBL] [Abstract][Full Text] [Related]
6. BRAF
Reischmann N; Andrieux G; Griffin R; Reinheckel T; Boerries M; Brummer T
Oncogene; 2020 Sep; 39(38):6053-6070. PubMed ID: 32792685
[TBL] [Abstract][Full Text] [Related]
7. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
Kim JH; Bae JM; Cho NY; Kang GH
Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
[TBL] [Abstract][Full Text] [Related]
8. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis.
Minoo P; Moyer MP; Jass JR
J Pathol; 2007 Jun; 212(2):124-33. PubMed ID: 17427169
[TBL] [Abstract][Full Text] [Related]
9. Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway.
Sakai E; Fukuyo M; Ohata K; Matsusaka K; Doi N; Mano Y; Takane K; Abe H; Yagi K; Matsuhashi N; Fukushima J; Fukayama M; Akagi K; Aburatani H; Nakajima A; Kaneda A
Int J Cancer; 2016 Apr; 138(7):1634-44. PubMed ID: 26510091
[TBL] [Abstract][Full Text] [Related]
10. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points.
O'Brien MJ; Yang S; Mack C; Xu H; Huang CS; Mulcahy E; Amorosino M; Farraye FA
Am J Surg Pathol; 2006 Dec; 30(12):1491-501. PubMed ID: 17122504
[TBL] [Abstract][Full Text] [Related]
11. Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea.
Kim KM; Lee EJ; Ha S; Kang SY; Jang KT; Park CK; Kim JY; Kim YH; Chang DK; Odze RD
Am J Surg Pathol; 2011 Sep; 35(9):1274-86. PubMed ID: 21836485
[TBL] [Abstract][Full Text] [Related]
12. RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation.
Yan HHN; Lai JCW; Ho SL; Leung WK; Law WL; Lee JFY; Chan AKW; Tsui WY; Chan ASY; Lee BCH; Yue SSK; Man AHY; Clevers H; Yuen ST; Leung SY
Gut; 2017 Sep; 66(9):1645-1656. PubMed ID: 27329244
[TBL] [Abstract][Full Text] [Related]
13. Integrative Genome-Scale DNA Methylation Analysis of a Large and Unselected Cohort Reveals 5 Distinct Subtypes of Colorectal Adenocarcinomas.
Fennell L; Dumenil T; Wockner L; Hartel G; Nones K; Bond C; Borowsky J; Liu C; McKeone D; Bowdler L; Montgomery G; Klein K; Hoffmann I; Patch AM; Kazakoff S; Pearson J; Waddell N; Wirapati P; Lochhead P; Imamura Y; Ogino S; Shao R; Tejpar S; Leggett B; Whitehall V
Cell Mol Gastroenterol Hepatol; 2019; 8(2):269-290. PubMed ID: 30954552
[TBL] [Abstract][Full Text] [Related]
14. Involvement of the serrated neoplasia pathway in inflammatory bowel disease-related colorectal oncogenesis.
Bossard C; Denis MG; Bézieau S; Bach-Ngohou K; Bourreille A; Laboisse CL; Mosnier JF
Oncol Rep; 2007 Nov; 18(5):1093-7. PubMed ID: 17914558
[TBL] [Abstract][Full Text] [Related]
15. Targeting the serrated pathway of colorectal cancer with mutation in BRAF.
Matos P; Gonçalves V; Jordan P
Biochim Biophys Acta; 2016 Aug; 1866(1):51-63. PubMed ID: 27345584
[TBL] [Abstract][Full Text] [Related]
16. The clinical significance of serrated polyps.
Huang CS; Farraye FA; Yang S; O'Brien MJ
Am J Gastroenterol; 2011 Feb; 106(2):229-40; quiz 241. PubMed ID: 21045813
[TBL] [Abstract][Full Text] [Related]
17. Traditional serrated adenoma has two pathways of neoplastic progression that are distinct from the sessile serrated pathway of colorectal carcinogenesis.
Tsai JH; Liau JY; Lin YL; Lin LI; Cheng YC; Cheng ML; Jeng YM
Mod Pathol; 2014 Oct; 27(10):1375-85. PubMed ID: 24603588
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions.
Ito M; Mitsuhashi K; Igarashi H; Nosho K; Naito T; Yoshii S; Takahashi H; Fujita M; Sukawa Y; Yamamoto E; Takahashi T; Adachi Y; Nojima M; Sasaki Y; Tokino T; Baba Y; Maruyama R; Suzuki H; Imai K; Yamamoto H; Shinomura Y
Int J Cancer; 2014 Dec; 135(11):2507-15. PubMed ID: 24752710
[TBL] [Abstract][Full Text] [Related]
19. The case for a genetic predisposition to serrated neoplasia in the colorectum: hypothesis and review of the literature.
Young J; Jass JR
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1778-84. PubMed ID: 17035382
[TBL] [Abstract][Full Text] [Related]
20. Serrated polyposis syndrome: molecular, pathological and clinical aspects.
Guarinos C; Sánchez-Fortún C; Rodríguez-Soler M; Alenda C; Payá A; Jover R
World J Gastroenterol; 2012 May; 18(20):2452-61. PubMed ID: 22654442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
